Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.52 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 9/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.49 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23202934 | 0.86 | LMNA (0.46) | RAB9ATTBK1TTBK2HTTNR2F2 | |
| SCHEMBL12412286 | 0.83 | HTT (0.41) | RAB9ATTBK1TTBK2HTTNR2F2 | |
| SCHEMBL12412276 | 0.83 | HTT (0.42) | RAB9ATTBK1TTBK2HTTNR2F2 | |
| SCHEMBL2181622 | 0.83 | HTT (0.43) | RAB9ATTBK1TTBK2HTTNR2F2 | |
| SCHEMBL23202839 | 0.81 | PDE5A (0.52) | RAB9AHTTNR2F2LMNAGALR3 | |
| SCHEMBL2178121 | 0.81 | SMN1; SMN2 (0.57) | RAB9AHTTNR2F2LMNAGALR3 | |
| SCHEMBL2180549 | 0.80 | HTT (0.39) | RAB9ATTBK1TTBK2HTTNR2F2 | |
| SCHEMBL12412302 | 0.80 | HTT (0.38) | RAB9ATTBK1TTBK2HTTNR2F2 | |
| SCHEMBL18733504 | 0.80 | RAB9A (0.54) | RAB9ATTBK1TTBK2HTTNR2F2 | |
| SCHEMBL23202826 | 0.79 | LMNA (0.46) | RAB9AHTTNR2F2PIP4K2CAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-25 | — | — | US | disclosed |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-18 | — | — | US | disclosed |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | The Trustees of Columbia University in they City of New York (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | UNIV COLUMBIA (US) | 2020-07-09 | — | — | US | disclosed |
| US-10626124-B2 | — | — | 2020-04-21 | — | — | US | disclosed |
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | NY STATE PSYCHIATRIC INSTITUTE | 2019-04-18 | — | — | US | disclosed |
| WO-2018067589-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
| WO-2017062500-A2 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-04-13 | — | — | WO | disclosed |
| US-8921382-B2 | Thiazolo[5,4-d] pyrimidines and their use as agrochemicals | DOW AGROSCIENCES, LLC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921382-B2 | Thiazolo[5,4-d] pyrimidines and their use as agrochemicals | DOW AGROSCIENCES, LLC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921382-B2 | Thiazolo[5,4-d] pyrimidines and their use as agrochemicals | DOW AGROSCIENCES, LLC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2521452-B1 | THIAZOLO[5,4-d]PYRIMIDINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2521452-B1 | THIAZOLO[5,4-d]PYRIMIDINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2011085084-A1 | THIAZOLO[5,4-d] PYRIMIDINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166164-A1 | THIAZOLO[5,4-d] PYRIMIDINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110166164-A1 | THIAZOLO[5,4-d] PYRIMIDINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110166164-A1 | THIAZOLO[5,4-d] PYRIMIDINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | RAB9A 214/4885TTBK1 391/4885TTBK2 457/4885 |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | RAB9A 214/4885TTBK1 391/4885TTBK2 457/4885 |
| US-10626124-B2 | — | MAPT, SQSTM1, TFEB | RAB9A 224/4885TTBK1 98/4885TTBK2 80/4885 |
| US-20110166164-A1 | THIAZOLO[5,4-d] PYRIMIDINES AND THEIR USE AS AGROCHEMICALS | DPYD, TYMS, TYMP | RAB9A 3424/4885TTBK1 1221/4885TTBK2 947/4885 |
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | RAB9A 214/4885TTBK1 391/4885TTBK2 457/4885 |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | RAB9A 214/4885TTBK1 391/4885TTBK2 457/4885 |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | RAB9A 214/4885TTBK1 391/4885TTBK2 457/4885 |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | RAB9A 214/4885TTBK1 391/4885TTBK2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.